US2005239203A1PendingUtilityA1
Regulation of endogenous gene expression in cells using zinc finger proteins
Individually held — no corporate assignee on recordPriority: Jan 12, 1999Filed: Jun 8, 2005Published: Oct 27, 2005
Est. expiryJan 12, 2019(expired)· nominal 20-yr term from priority
C07K 2319/09C12N 2750/14143C07K 2319/43C07K 2319/81C07K 2319/71A61K 48/005
51
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides methods for modulating expression of endogenous cellular genes using engineered zinc finger proteins.
Claims
exact text as granted — not AI-modified1 . A method for modulating expression of an endogenous gene in a cell, wherein the method comprises:
a) administering to the cell a nucleic acid molecule comprising a polynucleotide sequence encoding an engineered zinc finger protein, wherein the zinc finger protein comprises a plurality of zinc fingers and further wherein the zinc finger protein is partially randomized; and b) maintaining the cell under conditions in which the engineered zinc finger protein is expressed and binds to a target site in the gene.
2 . The method of claim 1 , wherein the zinc finger protein comprises at least one finger, or part of a finger, from a known zinc finger protein randomly combined with another heterologous finger, or part of a finger, from a known zinc finger protein.
3 . The method of claim 2 , wherein the endogenous cellular gene is the VEGF gene.
4 . The method of claim 2 , wherein the endogenous gene is a microbial gene.
5 . The method of claim 2 , wherein the endogenous gene is a viral gene.
6 . The method of claim 2 , wherein the cell is selected from the group consisting of animal cells, plant cells, bacterial cells, protozoal cells and fungal cells.
7 . The method of claim 6 , wherein the cell is a mammalian cell.
8 . The method of claim 7 , wherein the cell is a human cell.
9 . The method of claim 2 , wherein the zinc finger protein further comprises a regulatory domain.
10 . The method of claim 9 , wherein the regulatory domain is an activation domain.
11 . The method of claim 10 , wherein the regulatory domain is selected from the group consisting of VP 16, VP64 and the p65 subunit of NF kappa B.
12 . The method of claim 9 , wherein the regulatory domain is a repression domain.Join the waitlist — get patent alerts
Track US2005239203A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.